The global Urothelial Cancer drugs market size stood at USD 955 million in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period
Surging volume of patients suffering from urothelial cancer and high recurrence rate of patients, increasing prevalence of geriatric population across the globe, rising emergence and priority of targeted therapy among biopharmaceutical companies, rising awareness among people for early diagnosis and treatment, increasing adoption of unhealthy lifestyle of the people are some of the major as well as vital factors which will likely to augment the growth of the urothelial cancer drugs market in the projected timeframe of 2019-2028. On the other hand, rising development of new novel drugs by various pharmaceutical companies along with surging levels of investment in research activities which will further contribute by generating massive opportunities that will lead to the growth of the urothelial cancer drugs market in the above mentioned projected timeframe.
Increased knowledge about specific cancer biomarkers is fuelling revenue opportunities for diagnostic companies that aid in the treatment of various cancer patients through improvement in detection (both, accuracy and time spent). Technological advancements in the field of biotechnology have enhanced the identification of potential cancer biomarkers, and some of the recent diagnostics adopted for detection and disease progression of urothelial carcinoma include the Immuno-Histochemical assay test, In Situ hybridization test, biopsy, and cystoscopy.